NRX Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
NRX Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2017 to Q4 2023.
  • NRX Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $44.9M, a 6.78% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $44.9M +$2.85M +6.78% Dec 31, 2023 10-K 2024-03-29
Q4 2022 $42.1M +$9.81M +30.4% Dec 31, 2022 10-K 2024-03-29
Q4 2021 $32.2M +$11.8M +57.4% Dec 31, 2021 10-K 2023-03-31
Q4 2020 $20.5M +$20.5M Dec 31, 2020 10-K 2022-03-31
Q4 2019 $0 -$21.1M -100% Dec 31, 2019 10-K/A 2021-05-14
Q4 2018 $21.1M -$995K -4.51% Dec 31, 2018 10-K 2020-03-30
Q4 2017 $22.1M Dec 31, 2017 10-K 2019-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.